Year Published
- 2008 (0)
- 2009 (1) Apply 2009 filter
- (-) Remove 2010 filter 2010
- 2011 (0)
- 2012 (2) Apply 2012 filter
- 2013 (0)
- 2014 (0)
- 2015 (3) Apply 2015 filter
- 2016 (3) Apply 2016 filter
- 2017 (5) Apply 2017 filter
- (-) Remove 2018 filter 2018
- 2019 (0)
- 2020 (0)
- 2021 (0)
Research Topics
Populations
- Countries/Governments (0)
- Rural Populations (0)
- Smallholder Farmers (0)
- Women (0)
Types of Research
- Data Analysis (0)
- Literature Review (1) Apply Literature Review filter
- Portfolio Review (0)
- Research Brief (1) Apply Research Brief filter
Geography
- East Africa Region and Selected Countries (2) Apply East Africa Region and Selected Countries filter
- (-) Remove Global filter Global
- South Asia Region and Selected Countries (1) Apply South Asia Region and Selected Countries filter
- Southern Africa Region and Selected Countries (0)
- Sub-Saharan Africa (12) Apply Sub-Saharan Africa filter
- West Africa Region and Selected Countries (10) Apply West Africa Region and Selected Countries filter
Dataset
- ASTI (0)
- FAOSTAT (0)
- Farmer First (0)
- LSMS & LSMS-ISA (0)
- Other Datasets (0)
Current search
- (-) Remove Sustainable Agriculture & Rural Livelihoods filter Sustainable Agriculture & Rural Livelihoods
- (-) Remove Risk, Preferences, & Decision-Making filter Risk, Preferences, & Decision-Making
- (-) Remove Technology filter Technology
- (-) Remove Education & Training filter Education & Training
- (-) Remove 2010 filter 2010
- (-) Remove Global filter Global
- (-) Remove 2018 filter 2018
The private sector is the primary investor in health research and development (R&D) worldwide, with investment annual investment exceeding $150 billion, although only an estimated $5.9 billion is focused on diseases that primarily affect low and middle-income countries (LMICs) (West et al., 2017b). Pharmaceutical companies are the largest source of private spending on global health R&D focused on LMICs, providing $5.6 billion of the $5.9 billion in total private global health R&D per year. This report draws on 10-K forms filed by Pharmaceutical companies with the U.S. Securities and Exchange Commission (SEC) in the year 2016 to examine the evidence for five specific disincentives to private sector investment in drugs, vaccines and therapeutics for global health R&D: scientific uncertainty, weak policy environments, limited revenues and market uncertainty, high fixed costs for research and manufacturing, and imperfect markets. 10-K reports follow a standard format, including a business section and a risk section which include information on financial performance, investment options, lines of research, promising acquisitions and risk factors (scientific, market, and regulatory). As a result, these filings provide a valuable source of information for analyzing how private companies discuss risks and challenges as well as opportunities associated with global health R&D targeting LMICs.
This report presents data on selected agricultural commodities for the fourth quarter of 2009 (October through December 2009) and the months of January and February 2010, where available. More specifically, this report provides a summary of recent changes and trends in prices, demand, supply, and market conditions for key agricultural commodities. We find that agricultural commodity prices declined significantly in 2009 from peak 2008 levels. At the end of 2009, however, commodity prices began to rebound, which contributed to concerns over a possible return to high prices. In January and February, gains in the value of the U.S. Dollar helped keep agricultural commodity prices subdued.